Research Suggests Avandia Couldn't Beat Actos A Senate committee released documents on Tuesday suggesting that the maker of the diabetes drug Avandia suppressed a study a decade ago that might show the drug in a negative light. The revelations are playing out as the FDA considers whether to keep Avandia on the market.
NPR logo

Research Suggests Avandia Couldn't Beat Actos

  • Download
  • <iframe src="https://www.npr.org/player/embed/128506431/128506451" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript
Research Suggests Avandia Couldn't Beat Actos

Research Suggests Avandia Couldn't Beat Actos

  • Download
  • <iframe src="https://www.npr.org/player/embed/128506431/128506451" width="100%" height="290" frameborder="0" scrolling="no" title="NPR embedded audio player">
  • Transcript

RENEE MONTAGNE, Host:

More documents pointing to shortcomings with Avandia emerged yesterday and these came from Glaxo, though the drugmaker didn't want the public to see them. NPR's Scott Hensley reports.

SCOTT HENSLEY: Scott Hensley, NPR News, Washington.

Copyright © 2010 NPR. All rights reserved. Visit our website terms of use and permissions pages at www.npr.org for further information.

NPR transcripts are created on a rush deadline by Verb8tm, Inc., an NPR contractor, and produced using a proprietary transcription process developed with NPR. This text may not be in its final form and may be updated or revised in the future. Accuracy and availability may vary. The authoritative record of NPR’s programming is the audio record.